RENDITEZERTIFIKAT - FRESENIUS Stock

Certificat

DE000DGE2SU9

Market Closed - Boerse Frankfurt Warrants 13:35:03 2024-05-31 EDT
802.8 EUR +0.67% Intraday chart for RENDITEZERTIFIKAT - FRESENIUS
1 month+6.18%
3 months+14.78%
Date Price Change
24-05-31 802.8 +0.67%
24-05-30 797.4 +0.29%
24-05-29 795.1 -0.74%
24-05-28 801 -0.10%
24-05-27 801.8 +1.12%

Real-time Boerse Frankfurt Warrants

Last update May 31, 2024 at 01:35 pm

More quotes

Static data

Product typeOther Certificates
Buy / SellCALL
Underlying FRESENIUS SE & CO. KGAA
Issuer DZ BANK
WKN DGE2SU
ISINDE000DGE2SU9
Date issued 2020-08-07
Strike 42.27
Maturity 2027-02-01 (974 Days)
Parity 0.04 : 1
Emission price 1,000
Emission volume N/A
Settlement both
Currency EUR

Technical Indicators

Highest since issue 1,050
Lowest since issue 477.9
Spread 20
Spread %2.43%

Company Profile

Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - hospital administration and engineering (64.3%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (35.7%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (72.4%), North America (12.3%), Asia/Pacific (7.3%), Latin America (6.4%) and Africa (1.6%).
Sector
-
More about the company

Ratings for Fresenius SE & Co. KGaA

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Fresenius SE & Co. KGaA

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
29.28 EUR
Average target price
36.72 EUR
Spread / Average Target
+25.43%
Consensus